The FDA granted a priority review to a new drug application for glasdegib, an investigational oral smoothened inhibitor, for the treatment of adult patients with previously untreated acute myeloid leukemia in combination with low-dose cytarabine, a type of chemotherapy.
The FDA has approved the combination of the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) for the treatment of patients with BRAF-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
This year, the Pancreatic Cancer Action Network (PanCAN) awarded 9 grants to 12 researchers at 11 institutions in the US, Canada, and France, totaling $4.2 million.
Three patients developed uveal effusion syndrome, or a buildup of fluid in the suprachoroidal space in the eye, after initiating anti-PD-1/PD-L1 monoclonal antibody therapy.
The FDA has granted a priority review to a supplemental new drug application for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia, a type of non-Hodgkin lymphoma (NHL).
The Colorectal Cancer Alliance has opened its third annual survey of young-onset colorectal cancer patients, survivors, and caregivers, with the intent of learning about and tracking the medical and psycho-social experiences of this often overlooked group, which comprises 11 percent of colorectal cancer patients today.
Key recommendations from LUNGevity's Expanded Eligibility working group were published in the Journal of Thoracic Oncology.
The MMRF was honored for the 15th year for outstanding stewardship of donors’ funds.
CURE Media Group was honored with 4 Digital Health Awards from a competition that recognizes the world’s best digital health resources.
App aims to help people affected by cancer manage the symptoms of treatment, let go of anxiety, achieve deep, restful sleep and stay emotionally balanced.
The partnership aims to raise awareness and advance research for liver cancer.
Researchers at the National Institutes of Health are exploring whether CAR T-cell therapy can enhance the effectiveness of treatment with hematopoietic cell transplant (HCT) among patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy.
The FDA has approved bevacizumab (Avastin) for use in combination with carboplatin and paclitaxel, followed by bevacizumab monotherapy, for the treatment of patients with advanced ovarian cancer following initial surgical resection.
The FDA granted priority review to a supplemental Biologics License Application for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for an expanded age indication,
During a session at the 2018 ASCO Annual Meeting, June 1-5, in Chicago, Illinois, Nipp and fellow panelists Ellen Miller Sonet, MBA, JD, chief strategy and policy officer, CancerCare, and Gery P. Guy Jr, PhD, MPH, of the Centers for Disease Control and Prevention, discussed the financial burdens of cancer diagnosis and treatment, the barriers facing clinicians and patients in discussing these financial burdens, and solutions that can be implemented to alleviate the burden.
The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of patients with advanced, PD-L1–positive cervical cancer with disease progression on or after chemotherapy.
Chemotherapy-induced peripheral neuropathy (CIPN) is a potentially long-lasting adverse effect of cancer treatment for survivors of childhood cancer.
Based on results from the phase III MURANO trial, the FDA has granted a regular approval to venetoclax (Venclexta) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, following at least 1 prior therapy.
An off-the-shelf, dual-targeted chimeric antigen receptor (CAR) T-cell approach yielded positive results in preclinical specificity, functionality, and efficacy studies.
The FDA has granted a priority review to the PARP inhibitor talazoparib for the treatment of patients with germline BRCA–positive, HER2–negative locally advanced or metastatic breast cancer.
The FDA approved sargramostim (Leukine) for the treatment of adult and pediatric with hematopoietic subsyndrome of acute radiation syndrome (H-ARS).
The FDA approved pegfilgrastim-jmdb (Fulphila) as the first biosimilar to pegfilgrastim (Neulasta), a drug designed to reduce the risk of febrile neutropenia in patients treated with chemotherapy in certain types of cancer, according to a press release issued by the FDA.
Game-changing data published in the New England Journal of Medicine and presented during the 2018 ASCO Annual Meeting indicated that many women with HR+, HER2–, axillary node–negative breast cancer would see no significant benefit to having chemotherapy in addition to endocrine therapy.
As part of its continuing effort to recognize the important role an oncology nurse plays throughout a patient’s cancer journey, Oncology Nursing News® has kicked of the #AnOncNurseIs campaign.
This summer, Oncology Nursing News is kicking off a social media campaign that gives you the chance to tell the world what #AnOncNurseIs!
The FDA has granted breakthrough therapy designation to the kinase inhibitor crizotinib (Xalkori) for two indications.
The FDA has granted a priority review to the oral thrombopoietin-receptor agonist eltrombopag (Promacta) in combination with standard immunosuppressive therapy as a frontline treatment for severe aplastic anemia.
